First Trust NYSE Arca Biotechnology Index Fund (FBT)
| Assets | $1.79B |
| NAV | $164.09 |
| Expense Ratio | 0.55% |
| PE Ratio | 29.63 |
| Shares Out | 10.90M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Sep 23, 2015 |
| 1-Year Return | - |
| Volume | 26,430 |
| Open | 164.09 |
| Previous Close | 164.06 |
| Day's Range | 163.67 - 165.71 |
| 52-Week Low | 150.33 |
| 52-Week High | 186.51 |
| Beta | 0.98 |
| Holdings | 31 |
| Inception Date | Jun 19, 2006 |
About FBT
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Top 10 Holdings
34.87% of assets| Name | Symbol | Weight |
|---|---|---|
| BioNTech SE | BNTX | 3.76% |
| ACADIA Pharmaceuticals | ACAD | 3.54% |
| Agios Pharmaceuticals | AGIO | 3.51% |
| Qiagen | QGEN | 3.49% |
| Charles River Laboratories | CRL | 3.48% |
| Regeneron Pharmaceuticals | REGN | 3.46% |
| IQVIA Holdings | IQV | 3.45% |
| United Therapeutics | UTHR | 3.41% |
| Bio-Techne | TECH | 3.39% |
| Vertex Pharmaceuticals | VRTX | 3.37% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2015 | $0.0197 | Sep 30, 2015 |
| Jun 24, 2015 | $0.0649 | Jun 30, 2015 |
| Mar 25, 2015 | $0.0476 | Mar 31, 2015 |
| Dec 23, 2014 | $0.0524 | Dec 31, 2014 |
News
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Smart Beta ETF report for FBT
Can Biotech ETFs Gain From Positive Booster Update?
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
ETF Sectors to Bet on Positive Vaccine News
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
Can't Get Enough Biotech Exposure in Your Portfolio?
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, ...
7 Biotech Stocks To Buy For Profit From The Vaccine Crunch
As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on Inves...
Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
3 Healthcare ETFs to Buy for Health and Safety
Not all healthcare ETFs are the same and as this group of three proves, that can be a positive for savvy investors. The post 3 Healthcare ETFs to Buy for Health and Safety appeared first on InvestorPlace.
Encouraging Election Year History for this Biotech ETF
Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fund ...
How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?
Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.
Election History Says Buy Biotech Dip
Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ignor...
Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress
AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.
Post-Pandemic Stars Could Align For This Biotech ETF
These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.